Predictive processing: a circuit approach to psychosis
Predictive processing is a computational framework that aims to explain how the brain processes sensory information by making predictions about the environment and minimizing prediction errors. It can also be used to explain some of the key symptoms of psychotic disorders such as schizophrenia. In my talk, I will provide an overview of our progress in this endeavor.
Neurosurgery for Mental Disorders: Challenging Mindsets; Combining Neuroimaging and Neurophysiology in Parkinson’s Disease
On Wednesday, October 26th, at noon ET / 6PM CET, we will host Kara Johnson, PhD, and Ludvic Zrinzo, MD PhD, for the inaugural session of our newly conceived talk series format entitled "Stimulating Brains". Kara A. Johnson, a postdoctoral fellow in Dr. Coralie de Hemptinne’s lab at the University of Florida, will present her work on “Combining imaging and neurophysiology in Parkinson’s disease”. Ludvic Zrinzo, Professor of functional neurosurgery and head of the University College London functional neurosurgery unit, will give us a glimpse at the “Person behind the science”, and give a talk on “Neurosurgery for mental disorders: challenging mindsets”. The talks will be followed by a shared discussion. You can register via talks.stimulatingbrains.org to receive the (free) Zoom link!
Emerging Treatment Options in Psychiatry
The World Health Organization (WHO) estimates that untreated mental disorders accountfor 13% of the total global burden of disease, and by 2030, depression alone will be the leadingcause of disability around the world – outpacing heart disease, cancer, and HIV. This grim pictureis further compounded by the mental health burden delivered by the coronavirus pandemic.The lack of novel treatment options in psychiatry is restricted by a limited understanding in theneuroscience basis of mental disorders, availability of relevant biomarkers, poor predictability inanimal models, and high failure rates in psychiatric drug development. However, theannouncement in 2019 from the Federal Drug Administration (FDA) for approvals of newinterventions for treatment-resistant depression (intranasal esketamine) and postpartumdepression (i.v. brexanolone), demand critical attention. Novel public-private partnerships indrug discovery, new translational data on co-morbid biology, in particular the ascendance ofpsycho-immunology, have highlighted the arrival of a new frontier in biological psychiatryresearch for depressive disorders.